NCT05417282 - MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Cognitive Dysfunction, Cognitive Disorder

Interventions

DRUG

MW151

Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.

Trial Locations (1)

Northwestern Memorial HealthCare, Central DuPage Hospital, Warrenville Cancer Center, Winfield